Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | SMARCA5 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
mRNA | PPP4R3A | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
mRNA | FXYD6 | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
mRNA | GMIP | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-05 |
mRNA | BEST1 | CTRPv2 | pan-cancer | AAC | -0.14 | 2e-05 |
mRNA | C15orf38-AP3S2 | CTRPv2 | pan-cancer | AAC | -0.15 | 2e-05 |
mRNA | KCNS1 | CTRPv2 | pan-cancer | AAC | -0.14 | 2e-05 |
mRNA | MAU2 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
mRNA | POLD4 | CTRPv2 | pan-cancer | AAC | -0.14 | 2e-05 |
mRNA | PRRC2B | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |